-
Abraham S, Choi JG, Ortega NM, Zhang J, Shankar P, Swamy NM, 2016: Gene therapy with plasmids encoding IFN-beta or IFN-alpha14 confers long-term resistance to HIV-1 in humanized mice[J]. Oncotarget, 7, 78412-78420.
-
Bosinger SE, Utay NS, 2015: Type Ⅰ interferon: understanding its role in HIV pathogenesis and therapy[J]. Curr HIV/AIDS Rep, 12, 41-53. doi: 10.1007/s11904-014-0244-6
-
Bosinger SE, Li Q, Gordon SN, Klatt NR, Duan L, Xu L, Francella N, Sidahmed A, Smith AJ, Cramer EM, Zeng M, Masopust D, Carlis JV, Ran L, Vanderford TH, Paiardini M, Isett RB, Baldwin DA, Else JG, Staprans SI, Silvestri G, Haase AT, Kelvin DJ, 2009: Global genomic analysis reveals rapid control of a robust innate response in SIV-infected sooty mangabeys[J]. J Clin Investig, 119, 3556-3572.
-
Carnathan D, Lawson B, Yu J, Patel K, Billingsley JM, Tharp GK, Delmas OM, Dawoud R, Wilkinson P, Nicolette C, Cameron MJ, Sekaly RP, Bosinger SE, Silvestri G, Vanderford TH (2018) Reduced chronic lymphocyte activation following Interferon-alpha blockade in the acute phase of SIV infection in rhesus macaques. J Virol. https://doi.org/10.1128/jvi.01760-17
-
Cheng L, Ma J, Li J, Li D, Li G, Li F, Zhang Q, Yu H, Yasui F, Ye C, Tsao LC, Hu Z, Su L, Zhang L, 2017: Blocking type Ⅰ interferon signaling enhances T cell recovery and reduces HIV-1 reservoirs[J]. J Clin Investig, 127, 269-279.
-
Davidson S, Crotta S, McCabe TM, Wack A, 2014: Pathogenic potential of interferon alphabeta in acute influenza infection[J]. Nat Commun, 5, 3864-. doi: 10.1038/ncomms4864
-
Dunham RM, Vujkovic-Cvijin I, Yukl SA, Broadhurst MJ, Loke P, Albright RG, Wong JK, Lederman MM, Somsouk M, Hunt PW, Martin JN, Deeks SG, McCune JM, 2014: Discordance between peripheral and colonic markers of inflammation during suppressive ART[J]. J Acquir Immune Defic Syndr, 65, 133-141. doi: 10.1097/01.qai.0000437172.08127.0b
-
El-Diwany R, Soliman M, Sugawara S, Breitwieser F, Skaist A, Coggiano C, Sangal N, Chattergoon M, Bailey JR, Siliciano RF, Blankson JN, Ray SC, Wheelan SJ, Thomas DL, Balagopal A, 2018: CMPK2 and BCL-G are associated with type 1 interferon-induced HIV restriction in humans[J]. Sci Adv, 4, eaat0843-. doi: 10.1126/sciadv.aat0843
-
Fernandez S, Tanaskovic S, Helbig K, Rajasuriar R, Kramski M, Murray JM, Beard M, Purcell D, Lewin SR, Price P, French MA, 2011: CD4+ T-cell deficiency in HIV patients responding to antiretroviral therapy is associated with increased expression of interferon-stimulated genes in CD4+ T cells[J]. J Infect Dis, 204, 1927-1935. doi: 10.1093/infdis/jir659
-
Fletcher CV, Staskus K, Wietgrefe SW, Rothenberger M, Reilly C, Chipman JG, Beilman GJ, Khoruts A, Thorkelson A, Schmidt TE, Anderson J, Perkey K, Stevenson M, Perelson AS, Douek DC, Haase AT, Schacker TW, 2014: Persistent HIV-1 replication is associated with lower antiretroviral drug concentrations in lymphatic tissues[J]. Proc Natl Acad Sci USA, 111, 2307-2312. doi: 10.1073/pnas.1318249111
-
Garcia-Sastre A, Biron CA, 2006: Type 1 interferons and the virus-host relationship: a lesson in detente[J]. Science, 312, 879-882. doi: 10.1126/science.1125676
-
Hardy GA, Sieg S, Rodriguez B, Anthony D, Asaad R, Jiang W, Mudd J, Schacker T, Funderburg NT, Pilch-Cooper HA, Debernardo R, Rabin RL, Lederman MM, Harding CV, 2013: Interferon-alpha is the primary plasma type-Ⅰ IFN in HIV-1 infection and correlates with immune activation and disease markers[J]. PLoS ONE, 8, e56527-. doi: 10.1371/journal.pone.0056527
-
Harris LD, Tabb B, Sodora DL, Paiardini M, Klatt NR, Douek DC, Silvestri G, Muller-Trutwin M, Vasile-Pandrea I, Apetrei C, Hirsch V, Lifson J, Brenchley JM, Estes JD, 2010: Downregulation of robust acute type Ⅰ interferon responses distinguishes nonpathogenic simian immunodeficiency virus (SIV) infection of natural hosts from pathogenic SIV infection of rhesus macaques[J]. J Virol, 84, 7886-7891. doi: 10.1128/JVI.02612-09
-
Henrich TJ, Hatano H, Bacon O, Hogan LE, Rutishauser R, Hill A, Kearney MF, Anderson EM, Buchbinder SP, Cohen SE, Abdel-Mohsen M, Pohlmeyer CW, Fromentin R, Hoh R, Liu AY, McCune JM, Spindler J, Metcalf-Pate K, Hobbs KS, Thanh C, Gibson EA, Kuritzkes DR, Siliciano RF, Price RW, Richman DD, Chomont N, Siliciano JD, Mellors JW, Yukl SA, Blankson JN, Liegler T, Deeks SG, 2017: HIV-1 persistence following extremely early initiation of antiretroviral therapy (ART) during acute HIV-1 infection: an observational study[J]. PLoS Med, 14, e1002417-. doi: 10.1371/journal.pmed.1002417
-
Huang KJ, Su IJ, Theron M, Wu YC, Lai SK, Liu CC, Lei HY, 2005: An interferon-gamma-related cytokine storm in SARS patients[J]. J Med Virol, 75, 185-194. doi: 10.1002/(ISSN)1096-9071
-
Hunt PW, 2012: HIV and inflammation: mechanisms and consequences[J]. Curr HIV/AIDS Rep, 9, 139-147. doi: 10.1007/s11904-012-0118-8
-
Jacquelin B, Mayau V, Targat B, Liovat AS, Kunkel D, Petitjean G, Dillies MA, Roques P, Butor C, Silvestri G, Giavedoni LD, Lebon P, Barre-Sinoussi F, Benecke A, Muller-Trutwin MC, 2009: Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type Ⅰ IFN response[J]. J Clin Investig, 119, 3544-3555.
-
Johns TG, Kerry JA, Veitch BA, Mackay IR, Tutton PJ, Tymms MJ, Cheetham BF, Hertzog PJ, Linnane AW, 1990: Pharmacokinetics, tissue distribution, and cell localization of[J]. Cancer Res, 50, 4718-4723.
-
Lavender KJ, Gibbert K, Peterson KE, Van Dis E, Francois S, Woods T, Messer RJ, Gawanbacht A, Muller JA, Munch J, Phillips K, Race B, Harper MS, Guo K, Lee EJ, Trilling M, Hengel H, Piehler J, Verheyen J, Wilson CC, Santiago ML, Hasenkrug KJ, Dittmer U, 2016: Interferon alpha subtype-specific suppression of HIV-1 infection in vivo[J]. J Virol, 90, 6001-6013. doi: 10.1128/JVI.00451-16
-
Liu SY, Sanchez DJ, Aliyari R, Lu S, Cheng G, 2012: Systematic identification of type Ⅰ and type Ⅱinterferon-induced antiviral factors[J]. Proc Natl Acad Sci USA, 109, 4239-4244. doi: 10.1073/pnas.1114981109
-
Lorenzo-Redondo R, Fryer HR, Bedford T, Kim EY, Archer J, Pond SLK, Chung YS, Penugonda S, Chipman J, Fletcher CV, Schacker TW, Malim MH, Rambaut A, Haase AT, McLean AR, Wolinsky SM, 2016: Persistent HIV-1 replication maintains the tissue reservoir during therapy[J]. Nature, 530, 51-56. doi: 10.1038/nature16933
-
Marshall HD, Urban SL, Welsh RM, 2011: Virus-induced transient immune suppression and the inhibition of T cell proliferation by type Ⅰ interferon[J]. J Virol, 85, 5929-5939. doi: 10.1128/JVI.02516-10
-
Massanella M, Tural C, Papagno L, Garcia E, Jou A, Bofill M, Autran B, Clotet B, Blanco J, 2010: Changes in T-cell subsets in HIV-HCV-coinfected patients during pegylated interferon-alpha2a plus ribavirin treatment[J]. Antivir Ther, 15, 333-342. doi: 10.3851/IMP1531
-
Muller U, Steinhoff U, Reis LF, Hemmi S, Pavlovic J, Zinkernagel RM, Aguet M, 1994: Functional role of type Ⅰ and type Ⅱ interferons in antiviral defense[J]. Science, 264, 1918-1921. doi: 10.1126/science.8009221
-
Ng CT, Sullivan BM, Teijaro JR, Lee AM, Welch M, Rice S, Sheehan KC, Schreiber RD, Oldstone MB, 2015: Blockade of interferon beta, but not interferon alpha, signaling controls persistent viral infection[J]. Cell Host Microbe, 17, 653-661. doi: 10.1016/j.chom.2015.04.005
-
Nganou-Makamdop K, Billingsley JM, Yaffe Z, O'Connor G, Tharp GK, Ransier A, Laboune F, Matus-Nicodemos R, Lerner A, Gharu L, Robertson JM, Ford ML, Schlapschy M, Kuhn N, Lensch A, Lifson J, Nason M, Skerra A, Schreiber G, Bosinger SE, Douek DC, 2018: Type Ⅰ IFN signaling blockade by a PASylated antagonist during chronic SIV infection suppresses specific inflammatory pathways but does not alter T cell activation or virus replication[J]. PLoS Pathog, 14, e1007246-. doi: 10.1371/journal.ppat.1007246
-
Palesch D, Bosinger SE, Mavigner M, Billingsley JM, Mattingly C, Carnathan D, Paiardini M, Chahroudi A, Vanderford T, Silvestri G (2018) Short-term pIFN-alpha2a treatment does not significantly reduce the viral reservoir of SIV-infected, ART-treated rhesus macaques. J Virol. https://doi.org/10.1128/jvi.00279-18
-
Pestka S, Krause CD, Walter MR, 2004: Interferons, interferon-like cytokines, and their receptors[J]. Immunol Rev, 202, 8-32. doi: 10.1111/imr.2004.202.issue-1
-
Rothenberger MK, Keele BF, Wietgrefe SW, Fletcher CV, Beilman GJ, Chipman JG, Khoruts A, Estes JD, Anderson J, Callisto SP, Schmidt TE, Thorkelson A, Reilly C, Perkey K, Reimann TG, Utay NS, Nganou Makamdop K, Stevenson M, Douek DC, Haase AT, Schacker TW, 2015: Large number of rebounding/founder HIV variants emerge from multifocal infection in lymphatic tissues after treatment interruption[J]. Proc Natl Acad Sci USA, 112, E1126-E1134. doi: 10.1073/pnas.1414926112
-
Sandler NG, Bosinger SE, Estes JD, Zhu RT, Tharp GK, Boritz E, Levin D, Wijeyesinghe S, Makamdop KN, del Prete GQ, Hill BJ, Timmer JK, Reiss E, Yarden G, Darko S, Contijoch E, Todd JP, Silvestri G, Nason M, Norgren RB Jr, Keele BF, Rao S, Langer JA, Lifson JD, Schreiber G, Douek DC, 2014: Type Ⅰ interferon responses in rhesus macaques prevent SIV infection and slow disease progression[J]. Nature, 511, 601-605. doi: 10.1038/nature13554
-
Schoggins JW, Wilson SJ, Panis M, Murphy MY, Jones CT, Bieniasz P, Rice CM, 2011: A diverse range of gene products are effectors of the type Ⅰ interferon antiviral response[J]. Nature, 472, 481-485. doi: 10.1038/nature09907
-
Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, O'Connell RJ, Rupert A, Chomont N, Valcour V, Kim JH, Robb ML, Michael NL, Douek DC, Ananworanich J, Utay NS, Rv254/Search RS, teams Sp, 2017: Persistent, Albeit reduced, chronic inflammation in persons starting antiretroviral therapy in acute HIV infection[J]. Clin Infect Dis, 64, 124-131. doi: 10.1093/cid/ciw683
-
Soper A, Kimura I, Nagaoka S, Konno Y, Yamamoto K, Koyanagi Y, Sato K, 2017: Type Ⅰ interferon responses by HIV-1 infection: association with disease progression and control[J]. Front Immunol, 8, 1823-.
-
Stacey AR, Norris PJ, Qin L, Haygreen EA, Taylor E, Heitman J, Lebedeva M, DeCamp A, Li D, Grove D, Self SG, Borrow P, 2009: Induction of a striking systemic cytokine cascade prior to peak viremia in acute human immunodeficiency virus type 1 infection, in contrast to more modest and delayed responses in acute hepatitis B and C virus infections[J]. J Virol, 83, 3719-3733. doi: 10.1128/JVI.01844-08
-
Teijaro JR, Walsh KB, Cahalan S, Fremgen DM, Roberts E, Scott F, Martinborough E, Peach R, Oldstone MB, Rosen H, 2011: Endothelial cells are central orchestrators of cytokine amplification during influenza virus infection[J]. Cell, 146, 980-991. doi: 10.1016/j.cell.2011.08.015
-
Teijaro JR, Ng C, Lee AM, Sullivan BM, Sheehan KC, Welch M, Schreiber RD, de la Torre JC, Oldstone MB, 2013: Persistent LCMV infection is controlled by blockade of type Ⅰ interferon signaling[J]. Science, 340, 207-211. doi: 10.1126/science.1235214
-
Teijaro JR, Studer S, Leaf N, Kiosses WB, Nguyen N, Matsuki K, Negishi H, Taniguchi T, Oldstone MB, Rosen H, 2016: S1PR1-mediated IFNAR1 degradation modulates plasmacytoid dendritic cell interferon-alpha autoamplification[J]. Proc Natl Acad Sci USA, 113, 1351-1356. doi: 10.1073/pnas.1525356113
-
Utay NS, Douek DC, 2016: Interferons and HIV infection: the good, the bad, and the ugly[J]. Pathog Immun, 1, 107-116. doi: 10.20411/pai.v1i1
-
Veazey RS, Pilch-Cooper HA, Hope TJ, Alter G, Carias AM, Sips M, Wang X, Rodriguez B, Sieg SF, Reich A, Wilkinson P, Cameron MJ, Lederman MM, 2016: Prevention of SHIV transmission by topical IFN-beta treatment[J]. Mucosal Immunol, 9, 1528-1536. doi: 10.1038/mi.2015.146
-
Walsh KB, Teijaro JR, Wilker PR, Jatzek A, Fremgen DM, Das SC, Watanabe T, Hatta M, Shinya K, Suresh M, Kawaoka Y, Rosen H, Oldstone MB, 2011: Suppression of cytokine storm with a sphingosine analog provides protection against pathogenic influenza virus[J]. Proc Natl Acad Sci USA, 108, 12018-12023. doi: 10.1073/pnas.1107024108
-
Wilson EB, Yamada DH, Elsaesser H, Herskovitz J, Deng J, Cheng G, Aronow BJ, Karp CL, Brooks DG, 2013: Blockade of chronic type Ⅰ interferon signaling to control persistent LCMV infection[J]. Science, 340, 202-207. doi: 10.1126/science.1235208
-
Yan N, Chen ZJ, 2012: Intrinsic antiviral immunity[J]. Nat Immunol, 13, 214-222. doi: 10.1038/ni.2229
-
Zhen A, Rezek V, Youn C, Lam B, Chang N, Rick J, Carrillo M, Martin H, Kasparian S, Syed P, Rice N, Brooks DG, Kitchen SG, 2017: Targeting type Ⅰ interferon-mediated activation restores immune function in chronic HIV infection[J]. J Clin Investig, 127, 260-268.